Aurobindo Pharma gains as its arm launches generic equivalent of Advair Diskus in US market
Aurobindo Pharma is currently trading at Rs. 1670.80, up by 20.80 points or 1.26% from its previous closing of Rs. 1650.00 on the BSE.
The scrip opened at Rs. 1632.35 and has touched a high and low of Rs. 1,673.30 and Rs. 1632.35 respectively. So far 10724 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1682.00 on 13-Aug-2026 and a 52 week low of Rs. 1017.00 on 02-Sep-2025.
Last one week high and low of the scrip stood at Rs. 1,673.30 and Rs. 1586.30 respectively. The current market cap of the company is Rs. 96,145.65 crore.
The promoters holding in the company stood at 51.88%, while Institutions and Non-Institutions held 41.48% and 6.64% respectively.
Aurobindo Pharma’s step-down subsidiary -- Lannett Company LLC has launched the generic equivalent of Advair Diskus (fluticasone propionate and salmeterol inhalation powder), a product of GSK plc, in 100/50 mcg and 250/50 mcg strengths, in the US market. Lannett Company LLC is a wholly owned subsidiary of Aurobindo Pharma USA, Inc., which is a wholly owned subsidiary of the company.
This launch marks the first product from the company’s inhalation pipeline to be commercialized in the US, reflecting its continued focus on expanding its portfolio of complex and differentiated inhalation products. Advair Diskus in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
